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ABSTRACT 101 
Objectives: To identify genetic determinants of susceptibility to clinical vertebral fractures, an 102 
important complication of osteoporosis. Methods: Here we conduct a genome-wide 103 
association study in 1,553 postmenopausal women with clinical vertebral fractures and 4,340 104 
controls, with a 2-stage replication involving 1,028 cases and 3,762 controls. Potentially causal 105 
variants were identified using eQTL data from transiliac bone biopsies and bioinformatic 106 
studies. Results: A locus tagged by rs10190845 was identified on chromosome 2q13 which 107 
was significantly associated with clinical vertebral fracture (p=1.04x10-9) with a large effect 108 
size (odds ratio 1.74, 95% CI 1.06 – 2.6). Bioinformatic analysis of this locus identified several 109 
potentially functional SNPs which are associated with expression of the positional candidate 110 
genes TTL (Tubulin Tyrosine Ligase) and SLC20A1 (Solute Carrier Family 20 Member 1). 111 
Three other suggestive loci were identified on chromosomes 1p31, 11q12 and 15q11. All these 112 
loci were novel and had not previously been associated with BMD or clinical fractures. 113 
Conclusion: We have identified a novel genetic variant that is associated with clinical vertebral 114 
fractures by mechanisms that are independent of BMD. Further studies are now in progress to 115 
validate this association and evaluate the underlying mechanism.   116 
 117 
 118 
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1. INTRODUCTION 135 
Osteoporosis is a common disease with a strong genetic component. It is characterised by low 136 
bone mineral density (BMD), deterioration in the microstructural architecture of bone and an 137 
increased risk of fragility fractures. Vertebral fractures are an early and important complication 138 
of osteoporosis.[1] They are characterised by loss of height and deformity of the affected 139 
vertebrae and associated with increased risk of other fractures.[2] It has been estimated that 140 
between 8-30% of patients with radiological evidence of vertebral fractures (so called 141 
morphometric fractures) come to medical attention for reasons that are incompletely 142 
understood.[3,4] In contrast, other patients with vertebral fractures come to medical attention 143 
because of symptoms such as back pain, kyphosis, and height loss, and are defined as having 144 
clinical vertebral fractures.[5-7]  Clinical vertebral fractures are associated with a markedly 145 
increased risk of future fractures and increased mortality.[8] Major advances have been made 146 
in identifying genetic variants that regulate BMD and some variants have also been identified 147 
that predispose to non-vertebral fractures.[9-20]  However, the genetic determinants of 148 
vertebral fractures are poorly understood. A previous genome-wide association study (GWAS) 149 
published by Oei and colleagues involving a discovery cohort of 8,717 cases and 21,793 150 
controls failed to identify any significant genetic predictors of radiographic vertebral fracture 151 
at a genome-wide significant level.[21] However, in this study, the vertebral fractures were 152 
defined simply on the basis of morphometric analysis of spinal radiographs. It is well 153 
recognised however that the morphometric techniques employed in this study may have 154 
identified vertebral deformities that were not fractures.[22] The aim of the present study was 155 
to re-evaluate the predictors of clinical vertebral fractures by genome wide association study 156 
to try and gain new insights into this important and poorly understood clinical problem.  157 
 158 
2. PATIENTS AND METHODS 159 
The study involved a discovery phase with 1,553 clinical vertebral fracture cases and 4,340 160 
controls, a first replication phase of 694 cases and 2,105 controls, and a second replication 161 
phase of 334 cases and 1,657 controls, as summarised in Supplementary Table 1. The genome 162 
wide association study was performed using standard methodology as detailed in the 163 
Supplementary Text 1.  164 
 165 
3. RESULTS 166 
3.1. Characteristics of the study populations 167 
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The mean (±standard deviation) age of the patients with clinical vertebral fractures was 168 
71.3±9.3 years with a bone mineral density T-score at the lumbar spine of -2.72±1.4; and at the 169 
femoral neck of -2.57±1.1. The controls were not matched with the cases by age and did not 170 
undergo phenotyping for vertebral fracture on the basis that clinical vertebral fractures are 171 
uncommon in the general population (estimated incidence of 9.8/1000 person-years in 75-84 172 
year olds)[23]. While it is possible that clinical vertebral fractures may have occurred in some 173 
controls in later life this is unlikely to have substantially affected the results of the analysis, 174 
other than to have potentially slightly reduced its power.[24] This approach has been used 175 
previously for genome-wide studies in various common diseases including diabetes, Paget’s 176 
disease, and rheumatoid arthritis.[25,26] 177 
We identified 334 clinical vertebral fracture female cases from the UK Biobank cohort with a 178 
mean age (±standard deviation) of 58.8±7.7 years, and they were age-matched with 1,657 179 
female controls from the same cohort.  180 
3.2. Genome-wide association analysis of the discovery sample 181 
Since different genotyping platforms were used in the analysis of the different cohorts that 182 
constitute the discovery sample, association analysis was conducted following imputation of 183 
all genotypes into the CEU panel of HapMap II reference (see Patients and Methods section). 184 
Following imputation, we analysed 2,366,456 SNPs and identified 31 with suggestive evidence 185 
of association with vertebral fracture (p<10-4). Details are summarised in Supplementary Table 186 
2, the Manhattan and quantile-quantile plots are shown in Supplementary Figures 2 and 3. Each 187 
study was corrected by genomic control; genomic inflation factors ranged between =1.001 to 188 
=1.046 for genotyped SNPs and =1.006 to =1.036 after imputation. 189 
3.3. Replication and combined analysis 190 
We analysed the 31 suggestively associated SNPs identified in the discovery cohort 191 
(Supplementary Table 4) and seven additional SNPs that had been significantly associated with 192 
clinical fractures in a previous GWAS (Supplementary Table 5) in the replication sample.[10] 193 
Four SNPs showed nominal association (p<0.05) with clinical vertebral fractures at replication 194 
(Table 1). The combined discovery and replication analysis corrected for age identified one 195 
SNP (rs10190845) on chromosome 2q13 with genome-wide significant evidence of association 196 
with clinical vertebral fractures (p=1.27x10-8). The predisposing allele had a frequency of 0.034 197 
in cases compared with 0.022 in controls and the odds ratio for susceptibility to fracture was 198 
1.75 [95% CI: 1.44-2.12] (Figure 1). The results were similar without age correction (p=4.9x10-199 
8; odds ratio 1.66 [95% CI: 1.38-1.99]). Conditional analysis on rs10190845 did not reveal any 200 
secondary association signals at the locus (Supplementary Figure 4). Three other SNPs on 201 
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chromosomes 1p31, 11q12 and 15q11 were suggestively associated with vertebral fracture in 202 
the combined analysis (Table 1 and Supplementary Figures 5 and 6). None of these regions 203 
have previously been found to be associated with BMD or fracture in previous GWAS.[10,13]  204 
The top SNP (rs10190845) maps to a region which contains eleven potential candidate genes 205 
(Figure 2). This region has previously been implicated as a genetic regulator of bone density 206 
by Estrada and colleagues[10] who reported that rs17040773 within ANAPC1 (Anaphase 207 
Promoting Complex Subunit 1) was associated with femoral neck BMD (p=1.5x10-9), but not 208 
with clinical fractures (p=0.79). rs17040773 is not in linkage disequilibrium with rs10190845 209 
in our population (r2=0.006), and, in keeping with this, when we performed conditional analysis 210 
on rs17040773, we confirmed that rs10190845 remained significantly associated with clinical 211 
vertebral fractures (p=2.09x10-8; odds ratio 1.73 [95% CI: 1.43-2.09]). In order to test whether 212 
the variants associated with clinical vertebral fractures played a role in BMD, we tested the 213 
rs10190845 variant for association with volumetric vertebral bone mineral density in females 214 
on the dataset from Nielson and colleagues.[27] We did not find any association for the variant 215 
and BMD (p=0.23). This suggests that rs10190845 constitutes an independent signal which 216 
predisposes to clinical vertebral fracture by mechanisms that are independent of an effect on 217 
BMD. 218 
 219 
 220 
 221 
 222 
 223 
 224 
 225 
 226 
 227 
 228 
 229 
 230 
 231 
 232 
 233 
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Table 1. Variants showing suggestive or significant association with vertebral fracture  234 
    
Discovery 
(n = 5,893) 
Replication 
(n= 2,799) 
Combined* 
(n= 8,692) 
UK Biobank replication 
(n= 1,991) 
Total** 
(n= 10,683) 
Chr SNP Position A AF p 
OR 
(95% 
CI) 
AF p 
OR 
(95% 
CI) 
p 
OR  
(95% 
CI) 
I2 Q p AF p 
OR 
(95% 
CI) 
p 
OR 
(95% 
CI) 
I2 Q p 
2 rs10190845 112192944 A 0.03 2.4x10-5 
1.70 
(1.33-
2.17) 
0.05 1.60x10-4 
1.84 
(1.34-
2.53) 
1.27x10-8 
1.75 
(1.45-
2.12) 
5.9 0.39 0.05 0.027 
1.66 
(1.06-
2.60) 
1.04x10-9 
1.75 
(1.45-
2.12) 
0.0 0.48 
11 rs7121756 57980425 A 0.29 5.2x10-5 
1.22 
(1.11-
1.35) 
0.28 0.011 
1.23 
(1.05-
1.45) 
1.27x10-6 
1.23 
(1.13-
1.33) 
0.0 0.67 0.29 0.35 
1.09 
(0.91-
1.32) 
4.39x10-7 
1.22 
(1.13-
1.32) 
49.0 0.03 
15 rs2290492 92464744 A 0.23 3.4x10-5 
1.24 
(1.12-
1.37) 
0.21 0.021 
1.23 
(1.03-
1.46) 
1.61x10-6 
1.24 
(1.13-
1.35) 
53.7 0.02 0.22 0.44 
1.08 
(0.88-
1.33) 
2.51x10-7 
1.23 
(1.13-
1.33) 
75.6 1.1x10-5 
1 rs1360181 68248452 C 0.16 8.4x10-5 
1.25 
(1.12-
1.41) 
0.17 0.008 
1.30 
(1.07-
1.56) 
1.87x10-6 
1.26 
(1.14-
1.41) 
7.7 0.57 0.17 0.38 
0.90 
(0.72-
1.14) 
1.09x10-5 
1.22 
(1.12-
1.33) 
32.2 0.57 
 235 
The allele (A) and allele frequency (AF) for each of the variants is shown along with the p value for association, odds ratio (OR) and 95% 236 
confidence interval (95% CI). Q p values correspond to Cochran’s Q p-values. The values shown are adjusted for age but similar results were 237 
obtained for unadjusted association tests. Position refers to Human Genome Assembly GRCh38.p11. 238 
*Combined results showed the meta-analysis for discovery and replication stage. 239 
**Total results showed the meta-analysis including the second replication in the UK Biobank cohort. 240 
 241 
 242 
 243 
 244 
 245 
 246 
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A second replication for the significant hit on chromosome 2 and suggestive SNPs on 247 
chromosomes 1, 11 and 15 was performed in 334 clinical vertebral fracture cases and 1,657 248 
controls from UK Biobank. The top hit (rs10190845) on chromosome 2 was found nominally 249 
associated with clinical vertebral fractures (p=0.027, OR=1.66[1.060-2.600], MAF=0.049). No 250 
association was found for the suggestive SNPs in this cohort (Table 1).   251 
Meta-analysis of the discovery and the two replication stages showed a combined p-value for 252 
rs10190845=1.04x10-9 (OR=1.74[1.06-2.6]) with no evidence of heterogeneity between 253 
cohorts (I2=0.0, p=0.48) (Table 1). 254 
The SNPs rs7121756 on chromosome 11 and rs2290492 on chromosome 15 showed significant 255 
heterogeneity among cohorts (Cochrane’s Q<0.05), and a random effect analysis was 256 
performed. rs7121756 remained suggestively associated with clinical vertebral fractures 257 
(p=1.01x10-6), whilst rs2290492 showed a marginal association (p=0.004). 258 
3.4.Functional evaluation of chromosome 2q13 locus 259 
This analysis focused on a linkage disequilibrium block of approximately 700kb surrounding 260 
the top hit rs10190845. We identified a total of 936 SNPs within the region which were 261 
analysed in the GWAS (n=376) or which were in linkage disequilibrium (r2 value of > 0.7) 262 
with rs10190845, or which showed suggestive association to clinical vertebral fractures 263 
(p<5x10-3). We imputed the genotypes for the SNPs within the region of interest using the 1000 264 
Genomes phase 3 panel as reference and tested the SNPs for association with clinical vertebral 265 
fractures. We removed 878 of the SNPs since they showed no association with clinical vertebral 266 
fractures in our dataset (p>0.05). The remaining 58 candidate SNPs were tested for association 267 
with the level of expression of genes within the candidate locus using a bone-derived gene 268 
expression dataset (eQTLs)[28] (Tables 2, 3 and Supplementary Figure 7). This resulted in the 269 
identification of nine SNPs which were eQTLs for genes within the region. In order to gain 270 
insight into the functional basis of the association at 2q13 we used SuRFR[29] which integrates 271 
functional annotation and prior biological knowledge to identify potentially causal genetic 272 
variants, to assess these 9 SNPs along with the top hit rs10190845 (Table 2 and Supplementary 273 
Figure 7).274 
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Table 2. Functionality of SNPs in 2q13 region, ranked by SuRFR 275 
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1 rs35586251 0.17 A (0.02) 2.09x10-4 
1.69 
(1.28-2.24) 
Exon FBLN7 4.47 0 0 7 5 0.02 0 0 9.89 Yes TTL 6.6 x 10-6 
2 rs77172864 0.79 G (0.03) 4.96x10-5 
1.68 
(1.31-2.17) 
Intergenic 0.18 0 0 1 3 0.02 0 0 8.56 Yes SCL20A1 0.0001 
3 rs10190845 1 A (0.03) 2.4x10-5 
1.70 
(1.33-2.17) 
Intergenic 0 0 0 2 3 0.96 0 0 8.06 No - - 
4 rs77996972 0.22 T (0.02) 2.11x10-4 
1.69 
(1.28-2.23) 
Intron FBLN7 1.77 313 0 7 1 0.02 0 0 7.61 Yes 
TTL 
SLC20A1 
3.8 x 10-6 
5.5 x 10-5 
5 rs75814334 0.22 T (0.02) 2.11x10-4 
1.69 
(1.28-2.23) 
Intron FBLN7 0.43 239 0 8 1 0.02 0 0 7.56 Yes 
TTL 
SLC20A1 
2.1 x 10-6 
6.6 x 10-5 
6 rs74792868 0.22 A (0.02) 2.1x10-4 
1.69 
(1.28-2.24) 
Intron FBLN7 0 0 0 9 1 0.02 0 0 7.5 Yes 
TTL 
SLC20A1 
2.0 x 10-5 
2.8 x 10-5 
6 rs72943913 0.29 G (0.03) 5.48x10-5 
1.67 
(1.30-2.14) 
Intron ZC3H8 0.15 0 0 3 1 0.02 0 0 6.46 Yes SLC20A1 0.0001 
7 rs112275607 0.22 A (0.02) 2.13x10-4 
1.69 
(1.28-2.24) 
Intron FBLN7 0 0 0 8 1 0.02 0 0 6.83 Yes 
TTL 
SLC20A1 
2.8 x 10-6 
6.2 x 10-5 
8 rs113085288 0.06 T (0.02) 1.79x10-4 
1.70 
(1.29-2.24) 
Intron FBLN7 0 0 0 7 1 0.02 0 0 6.08 Yes SLC20A1 4.1 x10-6 
9 rs113428223 0.29 T (0.03) 4.55x10-5 
1.70 
(1.31-2.20) 
Intron ZC3H6 0 0 0 2 1 0.02 0 0 5.61 Yes SCL20A1 0.0001 
A (AF): allele (allele frequency); GERP: Genomic evolutionary rate profiling; DNAase HS: DNase hypersensitivity; DNase foot: DNase footprint; 276 
Ernst score: classes of chromatin states (recurrent combinations of chromatin marks); MAF: minor allele frequency; TFBS: transcription factor 277 
binding site. Gene names: FBLN7: Fibulin 7; ZC3H8: Zinc Finger CCCH-Type Containing 8; ZC3H6: Zinc Finger CCCH-Type Containing 6.  278 
 279 
 280 
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Table 3.  Correlation between genotypes for potentially functional SNP and bone-specific expression of genes in the candidate region  281 
 282 
RANK SNP GENE PROBE A1 A2 FRQ BETA SE P 
1 rs35586251 TTL 224896_s_at A G 0.017 0.65 0.13 6.62x10-6 
2 rs77172864 SLC20A1 230494_at G A 0.013 -0.46 0.11 0.00011 
4 rs77996972 TTL 224896_s_at T C 0.012 0.67 0.13 3.80x10-6 
   SLC20A1 230494_at T C 0.012 -0.49 0.11 5.50x10
-5 
5 rs75814334 TTL 224896_s_at T C 0.013 0.67 0.13 2.10x10-6 
   SLC20A1 230494_at T C 0.013 -0.48 0.11 6.60x10
-5 
6 rs74792868 TTL 224896_s_at A G 0.012 0.66 0.14 2.00x10-5 
   SLC20A1 230494_at A G 0.012 -0.53 0.12 2.80x10
-5 
6 rs72943913 SLC20A1 230494_at G A 0.013 -0.46 0.11 0.00011 
7 rs112275607 TTL 224896_s_at A G 0.013 0.67 0.13 2.80x10-6 
   SLC20A1 230494_at A G 0.013 -0.48 0.11 6.02x10
-5 
8 rs113085288 SLC20A1 230494_at T A 0.008 -0.72 0.14 4.06x10-6 
9 rs113428223 SLC20A1 230494_at T C 0.013 -0.46 0.11 0.0001 
 283 
The data shown are only for the associations which were significant after Bonferroni correction (p value for significance <0.0002).  A1: allele 1, 284 
A2: Allele 2, FRQ: frequency of allele 1, BETA: effect size on regression analysis referred to A1 allele, SE: standard error of beta estimate, probe 285 
IDs obtained from the Affymetrix HG U133 2.0 plus array. Gene names: TTL: Tubulin Tyrosine Ligase; SLC20A1: Solute Carrier Family 20 286 
Member 1 (also known as PIT1).  287 
 288 
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The top ranking variant identified by SuRFR, rs35586251, located within exon 3 of FBLN7 is 289 
a non-synonymous substitution (p.Val119Met). However, analysis using various in silico 290 
software tools yielded inconsistent results with regard to functionality of this SNP at the protein 291 
level (Supplementary Table 6). The other 9 SNPs are associated with expression of TTL, 292 
SCL20A or both genes. The variant that ranked top by SuRFR, rs35586251, was associated 293 
with increased expression of TTL (p=6.6x10-6). Four other variants were also associated with 294 
both increased expression of TTL and reduced expression of SLC20A1 (p-values ranging from 295 
2.1x10-6 to 10-5). The second ranking variant, rs77172864, in strong LD with the GWAS top 296 
hit (r2=0.79), was associated with reduced expression of SLC20A1 (p=10-4) (Tables 2 and 3).   297 
The variants listed on Table 2 were tested in the UK Biobank cohort for further association 298 
with clinical vertebral fractures (Supplementary Table 7). Although none of them was 299 
significantly associated with the trait, a trend of significance was found for SNPs rs72943913, 300 
rs77172864, and rs113428223 (p=0.06, OR=1.66), and all of them identified as eQTLs for 301 
SLC20A1 gene in bone. These variants showed a lower frequency (MAF=0.03) than the top hit 302 
(MAF=0.05), which could require a greater sample size to detect associations with the trait. 303 
3.5.  Association between clinical vertebral fractures and other osteoporosis related 304 
phenotypes 305 
In order to determine if there is overlap between the SNPs identified as associated with lumbar 306 
spine BMD in previous GWAS with those associated with clinical vertebral fracture in this 307 
study, we evaluated 50 SNPs that have been associated with lumbar spine BMD at a genome-308 
wide significant level in previous studies in our dataset.[10,11,13,30,31] Four variants were 309 
nominally associated with clinical vertebral fracture after Bonferroni correction (Table 4). We 310 
also analysed 15 variants previously associated with clinical fracture,[13]  of which three were 311 
associated with clinical vertebral fractures in this study. We also analysed the SNPs identified 312 
by Nielson and colleagues[27] as genome-wide significant predictors of volumetric vertebral 313 
bone mineral density for association with clinical vertebral fractures in our dataset. Of the six 314 
genome-wide significant SNPs identified by Nielson et al, we found that one was significantly 315 
associated with clinical vertebral fractures after Bonferroni correction (rs12742784, 316 
p=6.24x10-5). The BMD-increasing variants in Table 4 conferred a reduced risk of clinical 317 
vertebral fractures in our study, whilst the variants associated with appearance of clinical 318 
fractures in previous studies were also associated with a higher risk of developing a clinical 319 
vertebral fracture in our data.  320 
 321 
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Table 4. Association between known genetic determinants of spine BMD and clinical vertebral fractures in the combined GWAS dataset. 322 
Previous studies Present study 
Study SNP Locus Candidate gene Phenotype Method Allele Beta1 p Beta2 p 
Estrada rs1346004 2q24.3 GALNT3 LS-BMD DXA A ‐0.06 3.87x10‐30 +0.16 0.0002 
Estrada rs4727338 7q21.3 SLC25A13 LS-BMD DXA C +0.07 2.13x10‐35 -0.15 0.0004 
Estrada rs6426749 1p36.12 ZBTB40 LS-BMD DXA C +0.1 1.86x10‐44 -0.22 0.0003 
Styrkarsdottir rs7524102 1p36 WNT4 LS-BMD DXA A -0.11 9.2x10-9 +0.23 0.0002 
Estrada rs4727338 7q21.3 SLC25A13 Clinical fracture Clinical records 
and X-rays 
G +0.08 5.9x10-11 +0.14 0.0004 
Estrada rs6426749 1p36.12 ZBTB40 Clinical fracture Clinical records 
and X-rays 
G +0.07 3.6x10-6* +0.22 0.0003 
Estrada rs6959212 7p14.1 STARD3NL Clinical fracture Clinical records 
and X-rays 
T +0.05 7.2x10-5* +0.15 0.001 
Nielson rs12742784 1p36.12 ZBTB40 Vertebral BMD qCT imaging T +0.09 1.05x10-10 -0.20 6.24x10-5 
 323 
The variants shown are those that were significant after Bonferroni correction for testing 56 BMD variants (p threshold for association 0.0009) 324 
and 16 fracture variants (p threshold for association 0.003). *SNP significantly associated with clinical fracture after Bonferroni correction (p 325 
threshold at Estrada et al 5x10-4). 326 
Beta1 showed the effect for the previous studies (LS-BMD, clinical fracture and vertebral BMD). 327 
Beta2 showed the effect for the present study on clinical vertebral fracture 328 
Gene names: GALNT3: Polypeptide N-Acetylgalactosaminyltransferase 3); SLC25A13: Solute Carrier Family 25 Member 13; ZBTB40: Zinc 329 
Finger And BTB Domain Containing 40; WNT4: Wnt Family Member 4; STARD3NL: StAR Related Lipid Transfer Domain Containing 3 N-330 
Terminal Like). 331 
Method column shows the technique used to evaluate the BMD or assess the fracture (DXA: dual energy X-ray absorptiometry, CT: quantitative 332 
computerised tomography) 333 
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4. DISCUSSION 334 
Many advances have been made in defining the genetic determinants of bone mineral density 335 
and fractures through large scale genome-wide association studies, genome sequencing studies 336 
and linkage studies in rare bone diseases.[32] For example, linkage studies have shown that 337 
loss-of-function and gain-of-function variants in LRP5 cause early onset osteoporosis[33] and 338 
high bone mass[34] respectively, whereas loss of function mutations affecting SOST and LRP4 339 
have been identified as causes of high bone mass and osteosclerosis.[35,36] Genome-wide 340 
association studies and genome sequencing studies have also been successful in identifying 341 
multiple loci that regulate bone mineral density[9-11,30,37] and a smaller number that 342 
predispose to clinical fractures.[10,30]  343 
Although vertebral fractures are one of the most common and important complications of 344 
osteoporosis, relatively little is known about the genetic determinants of this type of 345 
fracture.[38] In a previous study of 8,717 cases and 21,793 controls, Oei and colleagues failed 346 
to identify any locus with significant evidence of association with morphometric vertebral 347 
fractures.[21] In the present study however, we were successful in identifying one genome-348 
wide significant variant that predisposed to clinical vertebral fractures, which was replicated in 349 
several populations. We also detected loci that might play a role in clinical vertebral fractures 350 
(showing suggestive association at the genome-wide level), but further studies need to be 351 
performed in further cohorts to confirm or refute these associations. A likely reason for the 352 
difference between our findings and those of Oei et al, is varying case definition. Here, we 353 
studied patients with clinical vertebral fractures as opposed to morphometric vertebral 354 
deformities, many of which may not be true fractures.[22] The genome-wide significant SNP 355 
identified in the present study, rs10190845, shows one of the largest effect size so far detected 356 
in the field of osteoporosis genetics (OR=1.75[1.45-2.12]). Most of the signals associated with 357 
BMD or fracture to date showed a very low effect (ORs between 0.90 and 1.10),[12,13] with a 358 
few exceptions.[20]  359 
rs10190845 maps to chromosome 2q13, a region previously associated with low femoral neck 360 
bone density.[10] However, when conditioning on rs17040773, the previously reported top 361 
SNP at the locus,[10] the association with rs10190845 remained significant, indicating that 362 
rs10190845 represents a novel signal. 363 
In order to determine if there was an overlap between the results of this study and those 364 
previously reported, we analysed 71 SNPs that have previously been associated with either 365 
spine BMD or clinical fractures and identified seven variants that were significantly associated 366 
with clinical vertebral fracture in this study, after Bonferroni correction (threshold for 367 
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significance 0.0009 for BMD and 0.003 for clinical fractures). However, the association for 368 
these variants did not reach genome-wide significance, therefore, they were not selected in the 369 
GWAS analysis. The SNPs associated with low BMD as well as increased risk of clinical 370 
fractures in previous studies were associated with an increased risk of clinical vertebral 371 
fractures in this study and those associated with an increased risk of clinical fractures in 372 
previous studies were associated with an increased risk of clinical vertebral fractures in this 373 
study.  374 
Furthermore, when we analysed six SNPs that were significantly associated with vertebral bone 375 
mineral density on quantitative computerised tomography (qCT) analysis[27] one locus on 376 
chromosome 1p36, close to ZBTB40, was identified and significantly associated with clinical 377 
vertebral fracture in this study. These results support the importance of ZBTB40 as a predictor 378 
of clinical fractures and suggest that the mechanism of association is most probably mediated 379 
by changes in BMD. The observations in this study, when taken together with the findings of 380 
Nielson and Estrada[10,27] indicate that there is a partial overlap between loci that regulate 381 
lumbar spine BMD, and clinical vertebral fractures. However, there are some genetic 382 
determinants of clinical vertebral fracture which are unique and which operate independently 383 
of BMD.  384 
In order to identify the mechanisms by which 2q13 predisposes to vertebral fracture we 385 
conducted bioinformatics analyses to determine if rs10190845 or other SNPs nearby were 386 
likely to be functional variants. These studies identified several potentially functional SNPs in 387 
the same LD block as rs10190845, which might account for the association we observed. The 388 
top ranking SNP from SuRFR analysis was rs35586251, which was strongly associated with 389 
expression of the TTL gene within the candidate locus (Supplementary Figure 8). However, the 390 
second ranking SNP, rs77172864 (Supplementary Figure 9), in strong LD with the GWAS top 391 
hit, was significantly associated with the expression of SLC20A1. Several other SNPs were also 392 
significantly associated with expression of TTL and/or SLC20A1, raising the possibility that 393 
alterations in expression of one or both genes might account for the predisposition to clinical 394 
vertebral fractures. Association analysis performed using UK Biobank cohort for these SNPs 395 
showed a trend of association for markers regulating SLC20A1 gene, which also showed some 396 
degree of linkage disequilibrium, with the GWAS top hit. The lack of significant association 397 
might be due to their low allele frequency (MAF=0.03), which means that a larger sample size 398 
may be required to detect a strong association. The Tubulin Tyrosine Ligase encoded by TTL 399 
is involved in regulation of the cytoskeleton. Previous studies have shown that TTL is involved 400 
in neuronal development[39] and injury signalling,[40] raising the possibility that variants that 401 
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regulate TTL might be involved in regulating pain perception, which could account for the fact 402 
that predisposing variants have not previously been associated with BMD. Other mechanisms 403 
might also be possible and further studies need to be performed in order to address the role of 404 
TTL in clinical vertebral fracture. The other main candidate gene, SLC20A1, encodes Pit1, 405 
which facilitates the entry of inorganic phosphate into the cytoplasm.[41] Previous studies have 406 
shown that SLC20A1 is involved in mineralisation.[42-45] Altered expression of this gene 407 
could convey risk for vertebral fractures via an effect on bone mineralisation. Although 408 
SLC20A1 presents as the candidate gene for association with clinical vertebral fractures in this 409 
study, it has not been identified previously as a predictor of BMD or fractures. This opens for 410 
alternative mechanisms, or that TTL rather than SLC20A1 is the candidate gene within the 2q13 411 
locus.  412 
Limitations of the study include the fact that the total sample size was relatively small and the 413 
power to detect alleles of modest effect size was limited. It is possible that we may have missed 414 
associations between rare variants and clinical vertebral fractures since the imputation we 415 
performed was against HapMap reference panel rather than larger panels that increase 416 
imputation power particularly against low frequency variants. Although case definition was 417 
clinically based, there was no significant heterogeneity in the associations we observed across 418 
centres.   419 
Strengths of the present study are that it has provided important new information on the genetic 420 
determinants of clinical vertebral fracture and that results, despite the sample size, have been 421 
validated in two independent replication stages.  422 
4.1. Conclusion 423 
Genome wide association analysis identified a significant association between a marker on 424 
chromosome 2 and clinical vertebral fractures in postmenopausal women, a finding validated 425 
in several independent populations.  426 
It is of interest that the top hit and other suggestive hits identified acted independently of BMD, 427 
bringing to attention other bone microarchitectural modalities that determine fracture 428 
susceptibility. This suggests that the variants identified might be acting as markers for 429 
perception of pain or other factors that are associated with the clinical presentation of vertebral 430 
fractures. We also found that some of the variants previously identified as regulators of spine 431 
BMD were associated with clinical vertebral fractures, but with effects that were weaker than 432 
the top hit and other suggestive hits. Taken together, the data suggest that the genetic basis of 433 
clinical vertebral fracture is complex involving variants that act independently of BMD as well 434 
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as those that are associated with spine BMD. Further research is now warranted to fully 435 
investigate the mechanisms involved.  436 
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Fig 1. Cohort specific association between rs10190845 and clinical vertebral fracture 645 
The point estimates (squares) and 95% confidence intervals (horizontal lines) for individual 646 
studies are shown with the summary indicated by the diamond using a fixed effect model. 647 
Summaries are shown for meta-analysis with discovery cohorts only (Summary_discovery), 648 
with the first replication cohorts only (Summary_replication), and for the whole 3-stage meta-649 
analysis (Summary_meta-analysis). “BRITISH-WTCCC” shows the results for the combined 650 
cohorts CAIFOS, AOGC, DOES, and EPIC, and the control cohort WTCCC2. “Scottish 651 
replication” corresponds to EDOS-ORCADES cohorts, “Italian_replication_1” study 652 
corresponds to Florence-InCHIANTI cohorts and “Italian_replication_2” study comprises the 653 
Turin and Siena cohorts. Cohort sizes are reflected by square dimensions. 654 
 655 
 656 
Fig 2. Regional association plots of susceptibility locus for clinical vertebral fracture 657 
The figure shows the results after imputation using 1000G v3 as reference panel. The SNPs are 658 
colour coded according to the extent of LD with the SNP showing the highest association signal 659 
from the combined analysis (represented as a purple diamond). The estimated recombination 660 
rates (cM/Mb) from HapMap CEU release 22 are shown as light blue lines, and the blue arrows 661 
represent known genes in the region. The red line shows the threshold for genome-wide 662 
significance (p = 5 x 10-8) 663 
